OBJECTIVES: Recent evidences have shown that glucosamine sulphate (GS) is a potentially effective treatment for osteoarthritis; however, it is unclear whether its use is cost-effective from the perspective of Thai Ministry of Public Health (MOPH). This study aims to estimate the cost-effectiveness of glucosamine sulphate (GS) compared with current care (CC) in osteoarthritis (OA) patients in Thailand. METHODS: A Markov model was used to simulate 10,000 hypothetical OA cohorts. The model comprised four health states including OA without total knee replacement (TKR), OA with TKR, OA after TKR, and death. Transition probabilities and health state utilities were obtained from published literature. Drug cost was obtained from the Drugs and Medical Supplies Information Center, MOPH, while the cost of TKR was based on the reimbursement rate provided by National Health Security Offi ce. The model estimated quality-adjusted life-years (QALYs), costs and incremental cost-effectiveness ratio (Cost/QALY gained) over life time horizon. Probabilistic sensitivity analyses (PSA) were undertaken. Both cost and health outcomes were discounted at 3%.
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COST-UTILITY ANALYSIS OF INTENSIVE LIFESTYLE INTERVENTIONS OR METFORMIN VERSUS STANDARD CARE IN THE PREVENTION OF TYPE 2 DIABETES IN HIGH-RISK SUBJECTS IN AN AUSTRALIAN SETTING. A SIMULATION ANALYSIS BASED ON THE LONG-TERM RESULTS OF THE DIABETES PREVENTION PROGRAM AND DIABETES PREVENTION PROGRAM OUTCOMES STUDY
Tucker DM, Palmer AJ Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia OBJECTIVES: The 3-year Diabetes Prevention Program (DPP) and 7-year follow-up Diabetes Prevention Program Outcomes Study (DPPOS) demonstrated that both intensive lifestyle interventions (ILI) and metformin led to reductions in the incidence of type 2 diabetes (T2D) versus standard care (control) in overweight or obese subjects with impaired glucose tolerance (IGT). Our aim was to project the long-term costutility of T2D prevention in an Australian setting, based on clinical results and resource utilization from the DPP + DPPOS. METHODS: We developed a semiMarkov, second-order Monte Carlo model to project the 10-year clinical and cost results of the DPP + DPPOS to patient lifetimes. Four health states were modeled: normoglycemia (NG); IGT; T2D and dead. Subjects started in IGT and progressed to T2D or NG, depending on the treatment received. State-specifi c mortality rates for NG, IGT, or T2D were used. We incorporated direct medical costs (from offi cial Australian published sources and the reimbursement perspective) and Australian utility and probability data. Total lifetime costs (C), quality-adjusted life-years (QALY) and incremental C/QALY-gained were calculated for ILI or metformin versus control. Outcomes were discounted at 5% annually. Validations and sensitivity analyses were performed. RESULTS: Delayed onset of T2D led to mean (standard deviation) QALY-gained of 0.38 (0.05) and 0.12 (0.04) years for ILI or metformin versus control, respectively. Costs savings of $282 (4222) per patient and cost increases of $1116 (4338) were projected for ILI or metformin versus control, respectively. ILI was dominant to control. C/QALY-gained for metformin versus control were $8757. Probability of acceptance at a willingness to pay threshold of $50,000 were 100% and 85% for ILI or metformin respectively. Results were most sensitive to probabilities of developing T2D, and costs of implementing the interventions. CONCLUSIONS: Lifetime projection of the DPP + DPPOS results found ILI dominant and metformin to be cost-effective versus control by current Australian standards.
CE3 COST-UTILITY ANALYSIS OF CHOLINESTERASE INHIBITORS IN THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE
Turongkaravee S Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Nonthaburi, Thailand OBJECTIVES: To evaluate the cost-utility of cholinesterase inhibitors (i.e., donepezil, rivastigmine, and galantamine) compared with no drug treatment in patients with mild to moderate Alzheimer's disease (AD) based on the governmental and societal perspectives and to estimate the budget impact when providing the cost-effective treatment. METHODS: A Markov model was used to evaluate the cost-utility of drug treatment options versus no drug treatment. Input parameters on the clinical effi cacy of cholinesterase inhibitors were obtained from systematic reviews and meta-analysis of international literature. The costs associated with AD were obtained from primary data collection at a university hospital and literature reviews. All costs were presented in 2008 Thai (THB). Probabilistic sensitivity analysis was performed to assess uncertainty surrounding model parameters. RESULTS: Based on both governmental and societal perspectives, galantamine was the most cost-effective compared with other drugs and no treatment option. The ICER at the base case scenario (i.e., patients with 60-year-old who had AD disease for 1 year, an Alzheimer Disease Assessment ScaleCognitive (ADAS-cog) score of 17, no presence of psychotic and extra-pyramidal symptoms (EPS) was 229,367 THB and 157,247 THB per QALY gained using the governmental and societal perspectives, respectively. Moreover, when providing galantamine for patients with EPS or patients with ADAS-cog score ranging from17 to 30 or patients having psychotic symptoms, galantamine was still more cost-effective compared with the base case scenario. Furthermore, the additional budgets required for providing galantamine for all Thai patients with mild to moderate AD at the fi rst year were 12,768 million THB. CONCLUSIONS: At the ceiling threshold of three times of gross domestic product (GDP) per capita (300,000 Baht per QALY), providing galantamine would be a cost-effective intervention for mild to moderate AD patients in Thailand. Galatamine would also be cost-effective at the threshold of onetime of GDP per capita (100,000 Baht per QALY) for patients with EPS. Top-down and bottom-up costing approaches were employed using societal perspective. The Barthel index (BI) was used to evaluate functional status and the EQ-5D was used to assess patients' quality of life. Effectiveness was defi ned as improving functional status and QALY. Multivariate analysis of variance, longitudinal logistic model, and multiple regressions were employed. Cost-effectiveness ratios per disability averted score and QALY gained were presented. A probabilistic sensitivity analysis was performed for uncertainty analysis. RESULTS: Compared to the control group, BI and QALY of patients with rehabilitation were signifi cantly improved (P < 0.01). The incremental cost-effectiveness ratio of providing of rehabilitation services for stroke patients was 73,191 Baht per QALY. Cost-effectiveness acceptability curves ensure that the rehabilitation services are likely to represent good value for money at the ceiling ratio of 200,000 Baht per QALY. CONCLUSIONS: The rehabilitation services for disabled stroke survivors were cost effective under the Thai health-care setting.
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